Main > ONCOLOGY (**) > Lymphoma>NHL>B-Cell>DLBCL R/R*** > Treatment > USA. G. CD79B Marker Inhibitor+>

---

USA. G. CD79B Marker Inhibitor+>'s subsections
(*) USA Approval Date: 2019. 06.10.
+Bendamustine+RituxiMAb
>Received 2 Prior Therapies
Company
Generic Name
TM
TM Web-Site
USA Patent Numbers

USA. G. CD79B Marker Inhibitor+>'s products
This section has no products